Navigation Links
BioNeutral Gains Initial Market Acceptance
Date:2/25/2013

NEWARK, N.J., Feb. 25, 2013 /PRNewswire/ -- Mark Lowenthal, President and CEO of BioNeutral Group, Inc. (OTCBB: BONU), a specialty technology-based life-science company, announced today that following an extensive product development and testing period, the initial reception of its products in the marketplace has far exceeded the Company's initial expectations.

In a letter to shareholders, Mr. Lowenthal stated, "After only six weeks in the marketplace, it now appears that our efforts are beginning to bear fruit. To date we have called on approximately 75 potential customers across a wide variety of trade classes in the relevant Health and Industrial markets and we're happy to say that the reception to our product offerings, both Ygiene™ 206 and Ogiene™ have far exceeded our expectations.  Over two thirds of the accounts we called on in the healthcare and life sciences related markets were interested in meeting with us, and to date, over 50% of those proceeded to initiate trials of our products with many more trials pending.  In the Industrial markets, we were equally well received with "across the board" interest from the full spectrum of market participants, i.e. end users, distributors, wholesalers and independent manufactures' in markets as diverse as Sanitation and Janitorial services, Mold Remediation and agriculture both here at home as well as abroad."

In his announcement, Mr. Lowenthal went on to say, "much still needs to be accomplished.  Our meetings are early ones. Trials, while going well, need to be completed and even more initiated.  However, it is becoming increasingly evident to us that our products meet a "need" in the marketplace that we are fast becoming increasingly able to meet.  In this regard, we have begun taking initial stocking orders with a growing amount anticipated, although as always there can be no assurance, over the next several months. While at thi
'/>"/>

SOURCE BioNeutral Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioNeutral Group Receives Positive Testing Results From A Global Independent Laboratory For Its Ygiene Sterilant Against Anthrax Spores
2. BioNeutral Group Appoints Mr. Mark Lowenthal as Chief Executive and President
3. BioNeutral Group Expands The Testing Of Its Ygiene Sterilant Against Anthrax Spores
4. BioNeutral Group Appoints A New Member to the Board of Directors
5. BioNeutral Group Receives $400,000 in Equity Financing
6. A possible answer for protection against chemical/biological agents, fuel leaks, and coffee stains
7. Two University of Colorado Cancer Center Studies Show that Silibinin, Found in Milk Thistle, Protects Against UV-Induced Skin Cancer
8. Tracking the Battle Against Breast Cancer With New Market Research
9. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
10. Doctors Without Borders and DNDi: Millions of Patients Still Waiting for Medical “Breakthroughs” Against Neglected Diseases
11. GeneTex Launches New Antibody Against Phosphorylated Histone H3 for Epigenetics Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Physicists Sergei Filippov (MIPT and Russian Quantum Center ... Brno, Czech Republic, and the Institute of Physics ... preserve quantum entanglement of particles passing through an ... long distances. Details are provided in an article ... (see preprint). , Quantum entangled particles are ...
(Date:7/23/2014)... MD (PRWEB) July 23, 2014 ... an LC/MS amino acid analysis system developed jointly ... the UF-Amino Station can analyze 38 amino acids ... The UF-Amino Station achieves high-speed analysis utilizing a ... The LCMS-2020 provides accurate analytical results even under ...
(Date:7/23/2014)... 2014 StemGenex® , the leading ... US aimed at improving the lives of patients dealing ... for Parkinson’s disease. StemGenex believes that a commitment ... are paramount when providing care to patients with degenerative ... cell therapy accessible to the millions of individuals currently ...
(Date:7/23/2014)... 23, 2014 regulated information -- UCB today announced ... pipeline with positive topline results from the latest ... was designed to evaluate the efficacy and safety ... without titration) compared to placebo, as adjunctive treatment ... not fully controlled despite treatment with one or ...
Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... Mass., Oct. 10 Targanta,Therapeutics Corporation (Nasdaq: TARG ... of 5,750,000 shares of its common stock at a ... the shares are being offered by,Targanta. Targanta has granted ... an additional 862,500 shares of common stock at the ...
... Signalife has received,additional sales orders in excess of ... Lowell Harmison,s most recent cross-country sales,initiative. These purchase orders ... the company anticipates achieving break-even status,by the end of ... of 2008 first,quarter. About Signalife: Signalife, Inc. ...
... 10 DermTech International, Inc.,a biotechnology company ... of melanoma and other diseases, today appointed ... Board. Dr. Quackenbush is a,Professor of Biostatistics ... and Professor of Computational Biology and Bioinformatics,at ...
Cached Biology Technology:Targanta Therapeutics Announces Pricing of its Initial Public Offering 2Signalife Continues to Procure Purchase Orders, Revenues 2DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Company's Scientific Advisory Board 2
(Date:7/24/2014)... gut that has gone undetected by scientists for decades. ... State University has found that more than half the ... named crAssphage, which infects one of the most common ... of bacteria is thought to be connected with obesity, ... in Nature Communications ., Robert A. Edwards, a ...
(Date:7/23/2014)... or neglected early in life are at risk ... In a new study, scientists have found that ... has implications for children,s long-term development. Previous studies ... and genetics interacted with that child,s experiences in ... In the new study, researchers were able to ...
(Date:7/23/2014)... of Defense recently awarded the STEMPREP Project at ... support its goal of increasing the number of ... minority middle school students for the two-summer classroom ... school students with summer opportunities at research labs. ... Simmons School of Education and Human Development, boasts ...
Breaking Biology News(10 mins):Newly discovered gut virus lives in half the world's population 2Newly discovered gut virus lives in half the world's population 3Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3Department of Defense awards $2.6 million grant to SMU STEM program for minority students 2
... NY, June 27, 2011Sophisticated genetic tools and techniques for ... in bone marrow will drive the successful application of ... Examples of these cutting-edge methods are presented in a ... of Human Gene Therapy , a peer-reviewed journal ...
... A team of researchers from the National Institute ... and the University of Maryland has made nano-sized ... from paints, cleaners, pesticides and other productsthat offer ... low-power room-temperature operation and the ability to detect ...
... Most previous studies have indicated that people in cities have ... country. By using more complex methods of analysis than in ... that people,s carbon emissions are practically the same in the ... CO 2 emissions that cause climate change are dependent ...
Cached Biology News:The promise of stem cell-based gene therapy 2Nanowire-based sensors offer improved detection of volatile organic compounds 2City dwellers produce as much CO2 as countryside people do 2
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... to ThPok ( Abpromise for all tested ... conjugated to KLH derived from within residues 500 ... the amino acid sequence is proprietary) ... Entrez Gene ID: 51043 ...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Rabbit polyclonal to SUR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide Entrez Gene ID: 6833 Swiss Protein ID: Q09428...
Biology Products: